Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
← catalyst calendarSponsored by Ocugen (industry) · OCGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-13 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Center Involved Diabetic Macular Edema
- Diabetic Macular Edema
Intervention
- Drug: OCU200
Primary outcomes
what the primary-completion date above is the date OFStudy Drug-related adverse events (SDAE)
measured 24 weeks
Treatment-emergent adverse events (TEAEs)
measured 24 weeks
Serious adverse events (SAEs)
measured 24 weeks
Permalink · OCGN's whole pipeline · Catalyst calendar · Every registered study · What changed